<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Infliximab: rheumatic diseases; Remicade; Infliximab: rheumatic diseases" /><meta name="IX" content="Remicade; Infliximab: rheumatic diseases" /><meta name="IXM" content="Infliximab: rheumatic diseases" /><title>INFLIXIMAB: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP6646-infliximab.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP6646-infliximab.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP6646-infliximab.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP6372-musculoskeletal-and-joint-diseases.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="PHP6373-drugs-used-in-rheumatic-diseases-and-gout.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm">10.1.3 Drugs that suppress the rheumatic disease process</a> &gt; <a href="PHP6607-cytokine-modulators.htm">Cytokine modulators</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP6644-golimumab.htm" title="Previous: GOLIMUMAB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP6650-remicade.htm#PHP6650-remicade" title="Next: Remicade®">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301005.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Disease-modifying Antirheumatic Drugs 92:36</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/9898-g.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Infliximab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: I &gt; Interactions of Infliximab</p></div></li></ul><ul><li><h3>British National Formulary (8)</h3></li><li><a href="PHP479-inflammatory-bowel-disease.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory bowel disease</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="PHP535-cytokine-modulators.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cytokine modulators</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response</p></div></li><li><a href="PHP538-infliximab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">INFLIXIMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response &gt; Cytokine modulators</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22infliximab%22%22infliximab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (8)</a></li></ul><ul><li><h3>BNF for Children (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP11193-inflammatory-bowel-disease.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory bowel disease</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP11238-cytokine-modulators.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cytokine modulators</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP11239-infliximab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">INFLIXIMAB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response &gt; Cytokine modulators</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22infliximab%22%22infliximab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/I04-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; I</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/9898-g.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Analgesics Anti-inflammatory Drugs and Antipyretics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/04972.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; I &gt; IN</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-I30.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; I</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D2304.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Infliximab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; I</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><?highlighter on?><h1>INFLIXIMAB</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int991-infliximab.htm">Infliximab</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">see under <a title="BNF:target-block: Infliximab-arthritis" href="PHP6607-cytokine-modulators.htm#PHP6612">Cytokine Modulators</a> above; inflammatory bowel disease (<a title="BNF:monograph: INFLIXIMAB" href="PHP538-infliximab.htm">section 1.5.3</a>); psoriasis (<a title="BNF:monograph: INFLIXIMAB" href="PHP7787-infliximab.htm">section 13.5.3</a>)</p></div> </div> <div id="PHP6647" class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">predisposition to infection; monitor for infection before, during, and for 6 months after treatment (see also Tuberculosis below); discontinue if new serious infection develops; hepatitis B virus—monitor for active infection; mild heart failure (discontinue if symptoms develop or worsen); demyelinating disorders (risk of exacerbation); history or development of malignancy; history of prolonged immunosuppressant or PUVA treatment in patients with psoriasis; <strong>interactions:</strong> Appendix 1 (infliximab) </p></div> <div class="cG"><div class="cE"><h3 class="cT">Tuberculosis</h3> <p class="cT">Patients should be evaluated for tuberculosis before treatment. Active tuberculosis should be treated with standard treatment (<a title="sub-section: Antituberculous drugs" href="PHP3588-antituberculosis-drugs.htm">section 5.1.9</a>) for at least 2 months before starting infliximab. Patients who have previously received adequate treatment for tuberculosis can start infliximab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting infliximab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with infliximab. Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Blood disorders</h3> <p class="cT">Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Hypersensitivity reactions</h3> <p class="cT">Hypersensitivity reactions (including fever, chest pain, hypotension, hypertension, dyspnoea, transient visual loss, pruritus, urticaria, serum sickness-like reactions, angioedema, anaphylaxis) reported during or within 1–2 hours after infusion (risk greatest during first or second infusion or in patients who discontinue other immunosuppressants). All patients should be observed carefully for 1–2 hours after infusion and resuscitation equipment should be available for immediate use. Prophylactic antipyretics, antihistamines, or hydrocortisone may be administered. Monitor for symptoms of delayed hypersensitivity if readministered after a prolonged period. Patients should be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity develop</p></div></div> </div> <div id="PHP6648" class="cL"><div class="cE"><h2 class="cN">Contra-indications </h2> <p class="cT">severe infections (see also under Cautions); moderate or severe heart failure</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">use only if essential; manufacturer advises adequate contraception during and for at least 6 months after last dose</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">amount probably too small to be harmful</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT" id="PHP6649">see under <a title="BNF:target-block: Cytokine inhibitor side-effects notes 10.1.3" href="PHP6607-cytokine-modulators.htm#PHP6619">Cytokine Modulators</a> and under Cautions above; also constipation, diarrhoea, dyspepsia, gastro-intestinal haemorrhage, gastro-oesophageal reflux, flushing, hypotension, hypertension, palpitation, tachycardia, sleep disturbances, dizziness, paraesthesia, hypoaesthesia, arthralgia, myalgia, epistaxis, alopecia, rash, ecchymosis, hyperhydrosis, new onset or worsening psoriasis, dry skin; <em>less commonly</em> hepatitis, cholecystitis, intestinal perforation, pancreatitis, heart failure, arrhythmia, bradycardia, syncope, peripheral ischaemia, pleurisy, pulmonary oedema, amnesia, agitation, confusion, nervousness, neuropathy, seizures, vaginitis, eye disorders, bullous eruption, cheilitis, seborrhoea, impaired healing, rosacea, hyperkeratosis, abnormal skin pigmentation; <em>rarely</em> pericardial effusion, vasospasm, interstitial lung disease, leukaemia, lymphoma, demyelinating disorders, Stevens-Johnson syndrome, toxic epidermal necrolysis; <em>also reported</em> hepatic failure</p></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul> <li><p><span class="cK">By intravenous infusion</span>, rheumatoid arthritis (in combination with methotrexate), <span class="cP">adult</span> over 18 years, 3 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 8 weeks; if response inadequate after 12 weeks, dose may be increased in steps of 1.5 mg/kg every 8 weeks, up to max. 7.5 mg/kg every 8 weeks; alternatively, 3 mg/kg may be given every 4 weeks; discontinue if no response by 12 weeks of initial infusion or after dose adjustment</p> <p>Ankylosing spondylitis, <span class="cP">adult</span> over 18 years, 5 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 6–8 weeks; discontinue if no response by 6 weeks of initial infusion</p> <p>Psoriatic arthritis (in combination with methotrexate), <span class="cP">adult</span> over 18 years, 5 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 8 weeks</p> </li> </ul></div></div> <div class="cAK"><h2>NICE Technology Appraisals</h2><p>See <a title="Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)" href="PHP6607-cytokine-modulators.htm#PHP6614">Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)</a></p><p>See <a title="Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)" href="PHP6607-cytokine-modulators.htm#PHP6616">Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)</a></p><p>See <a title="Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)" href="PHP6607-cytokine-modulators.htm#PHP6615">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</a></p><p>See <a title="Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)" href="PHP6607-cytokine-modulators.htm#PHP6618">Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="PHP6650-remicade.htm#PHP6650-remicade" title="Remicade®">Remicade®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP6644-golimumab.htm">Previous: GOLIMUMAB</a> | <a class="top" href="PHP6646-infliximab.htm#">Top</a> | <a accesskey="]" href="PHP6650-remicade.htm#PHP6650-remicade" title="Remicade®">Next: Remicade®</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>